CMMB Chemomab Therapeutics Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1534248 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY35.5%
TTM EPS YoY-53.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-69.5%
ROA-58.5%
ROIC (approx.)-1,446.2%
Asset turnover—
Leverage & solvency
Liabilities / assets10.7%
Debt / equity0.00x
Current ratio9.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.24x
Accruals ratio13.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| Cost of revenue | $2.33M | $2.46M | $4.39M | $5.14M | $3.31M |
| R&D expense | $5.83M | $11.33M | $18.38M | $16.98M | $6.33M |
| SG&A expense | $3.73M | $3.41M | $7.08M | $11.56M | $6.03M |
| Operating income | -$112.00M | -$103.00M | — | — | — |
| Pretax income | -$8.99M | -$13.95M | -$24.22M | -$28.18M | -$12.48M |
| Income tax | $0 | $0 | $0 | -$534,000 | $0 |
| Net income | -$8.99M | -$13.95M | -$24.22M | -$27.65M | -$12.48M |
| EBITDA | -$111.93M | -$102.95M | — | — | — |
| EPS (basic) | 0.02 | 0.04 | 0.10 | 0.12 | 0.06 |
| EPS (diluted) | 0.02 | 0.04 | 0.10 | 0.12 | 0.06 |
| Weighted avg. shares (diluted) | 510.23M | 359.05M | 235.00M | 227.59M | 207.47M |
| Balance sheet | |||||
| Cash & equivalents | $7.56M | $6.07M | $9.37M | $13.60M | $15.24M |
| Current assets | $13.43M | $16.04M | $20.90M | $41.74M | $62.69M |
| PP&E, net | $176,000 | $250,000 | $303,000 | $367,000 | $357,000 |
| Total assets | $13.81M | $16.96M | $22.15M | $43.06M | $64.35M |
| Current liabilities | $1.48M | $3.22M | $4.84M | $6.75M | $2.65M |
| Total liabilities | $1.48M | $3.43M | $5.15M | $6.84M | $2.89M |
| Shareholders' equity | $12.33M | $13.54M | $17.00M | $36.22M | $61.47M |
| Shares outstanding | — | 377.13M | 284.09M | 232.64M | 228.09M |
| Cash flow statement | |||||
| Operating cash flow | -$11.13M | -$15.39M | -$23.61M | -$20.37M | -$12.37M |
| Capital expenditure | $3,000 | $0 | $3,000 | $68,000 | $239,000 |
| Free cash flow | -$11.13M | -$15.39M | -$23.61M | -$20.44M | -$12.61M |
| Investing cash flow | $5.39M | $2.30M | $15.88M | $19.53M | -$45.19M |
| Financing cash flow | $7.16M | $9.87M | $3.50M | -$808,000 | $61.07M |
| Depreciation & amortization | $70,000 | $53,000 | $67,000 | $58,000 | $34,000 |
| Stock-based compensation | $623,000 | $617,000 | $1.49M | $3.21M | $2.02M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.